EuroQuity Blog

EuroQuity Stories : Pedro Lima Sea4Us

Last November 2020, during the 9th TAFTIE e-pitch session, the startup Sea4Us had the opportunity to pitch in front of investors. In this article, Sea4us tooked the time to talk about their project and the support they received from EuroQuity during the pitch session. 

@ João Rodrigues | CHIMERAVISUALS
@ João Rodrigues | CHIMERAVISUALS
What drove you to create/lead your company?

Pedro Lima's passion for science and the sea created the perfect conditions for the birth of the current Sea4Us.
With Sea4Us the convergence of a major will of finding a cure / relieve for a disease with no adequate treatment and the aim for helping people, became reality.
The development of new pharmaceutical drugs and the improvement of the living conditions of patients is the company’s main driving force.

What are your main goals currently, and which ones have you achieved or are you on track to achieve?

Sea4Us is a biotechnology company based in Sagres and Lisbon (Portugal) that is specialized in the discovery and early development of new pharmaceutical drugs based on novel marine compounds.
Sea4Us has developed a platform, based on marine biology and ion channels, that allows the identification of novel pharmaceutical drugs deriving from marine-living organisms for several unmet clinical needs that have ion channels as therapeutic targets. This drug discovery platform can be used to identify novel modulators for ion channels involved in different pathologies such as chronic pain, epilepsy, diabetes, cardiac arrhythmia, hypertension, and skin diseases, among others.
The company’s activity is focused in studying marine-living organisms’ compounds bioactivities, consequent biotechnological production or artificial chemical synthesis of bioactive pure compounds, and pharmaceutical development including non-clinical and early clinical trials.
One of these pathologies is chronic pain, for which Sea4Us is currently developing a therapy. Besides an analgesic for chronic pain, Sea4Us is also currently developing new treatments for channelopathies and other clinical indications.
Sea4Us has a new solution for chronic pain treatment that is highly disruptive compared to the current pain treatment solutions. Our extremely innovative approach shows a differentiated mode-of-action (acting directly in the "pain switch") that will give rise to a new class of pharmaceutical drugs with no expected adverse effects on the brain. The two already identified disruptive compounds (small molecules) will modulate specific ion channels in pain-sensing neurons (Kv).
Sea4Us has already performed “proof-of-concept” studies in different chronic pain models such as inflammatory pain, post-operative pain, orofacial pain, painful diabetic neuropathy, chemotherapy-induced peripheral neuropathy and visceral pain, which clearly show high efficacy in a widespread of applications in the chronic pain context and absence of acute toxicity in live animal models.

How has EuroQuity helped you in achieving these goals?

Euroquity has been an excellent partner for the publication of the fundraising intention and an indisputable partner that has allowed us to increase the visibility of Sea4Us.
In the area of training, Euroquity has functioned as a great source of information and learning for the entire management team.

Rédigé par Arélique Nguyen le Thursday, September 30th 2021
Stay informed by suscribing to our newsletter